The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Factors associated with early progression after ide-cel in patients with R/R multiple myeloma
Hamza Hashmi, MD, Medical University of South Carolina, Charleston, SC, explains the findings of a study investigating factors associated with early disease progression following treatment with idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory (R/R) multiple myeloma. The study identified high ferritin levels after lymphodepletion, high-risk cytogenetics, and prior BCMA-targeted therapy as factors associated with a high-risk of progression within three months of ide-cel treatment. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Consultancy, Speakers Bureau; GSK: Speakers Bureau; KARYOPHARM: Speakers Bureau; JANSSEN: Consultancy; BMS: Consultancy.
